StonvexLoading…
StonvexStonvexStonvexCore line items from DXC's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2026 2026-03-31 | Annual 2025 2025-03-31 | Annual 2024 2024-03-31 | Annual 2023 2023-03-31 |
|---|---|---|---|---|
Revenue | $12.64B | $12.87B | $13.67B | $14.43B |
Operating Income | $970.00M | $1.02B | $1.01B | $1.14B |
Net Income | $18.00M | $389.00M | $91.00M | $-568.00M |
EPS (Diluted) | $0.10 | $2.10 | $0.46 | $-2.48 |
Total Assets | $12.89B | $13.21B | $13.87B | $15.85B |
Total Liabilities | $9.68B | $9.71B | $10.80B | $12.03B |
Cash & Equivalents | $1.74B | $1.80B | $1.22B | $1.86B |
Free Cash Flow OCF − CapEx | $1.04B | $1.15B | $1.18B | $1.15B |
Shares Outstanding | 178.65M | 184.92M | 198.78M | 228.99M |